Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

In a recent study published in the journal Nutrients, researchers investigated the associations between urinary bisphenol A (BPA) concentrations (exposure) and the prostate-specific antigen (PSA; ...

Higher serum creatinine levels that are still within normal ranges are associated with a significantly increased risk of prostate cancer, according to a new study. Compared with patients in the lowest ...

Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for metastatic prostate cancer, ...

Researchers linking uric acid (UA) levels to the aggressiveness and progression of prostate cancer believe these findings can be used to study UA influence on prostate cancer–related mortality risk.